Overview

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Status:
Active, not recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Brii Biosciences Limited

Collaborator:

Vir Biotechnology, Inc.

Treatments:

Interferon-alpha
Interferons